AR096848A1 - Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) - Google Patents
Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)Info
- Publication number
- AR096848A1 AR096848A1 ARP140102528A ARP140102528A AR096848A1 AR 096848 A1 AR096848 A1 AR 096848A1 AR P140102528 A ARP140102528 A AR P140102528A AR P140102528 A ARP140102528 A AR P140102528A AR 096848 A1 AR096848 A1 AR 096848A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- independently
- hydrogen atom
- ring
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 241000343557 Melanina Species 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000005750 substituted cyclic group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 102100038942 Glutamate receptor ionotropic, NMDA 3A Human genes 0.000 abstract 1
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 abstract 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 abstract 1
- 108091008638 NR4A Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000007717 exclusion Effects 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 108091008589 nuclear estrogen receptors Proteins 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proporciona un compuesto que tiene una acción antagonista del receptor de la hormona concentradora de melanina y que es útil como agente para la profilaxis o el tratamiento de la obesidad y similares. Reivindicación 1: Un compuesto representado por la fórmula (1), caracterizado porque el anillo Ar es un anillo aromático además sustituido en forma opcional; L¹ es O, S(O)ₘ₁, NR³A o CR³BR³C; L² es O, S(O)ₘ₂, NR⁴A o CR⁴BR⁴C; (con la exclusión de la combinación en que L¹ sea distinto de CR³BR³C y L² sea distinto de CR⁴BR⁴C); m1 y m2 son cada uno en forma independiente un número entero de 0 a 2; R³A y R⁴A son cada uno en forma independiente un átomo de hidrógeno o un grupo hidrocarburo sustituido en forma opcional; R³B, R³C, R⁴B y R⁴C son cada uno en forma independiente un átomo de hidrógeno o un sustituyente; cuando L¹ es CR³BR³C y el anillo Ar tiene sustituyente(s), R³B y el sustituyente se encuentran unidos en forma opcional entre sí para formar un anillo sustituido en forma opcional; X¹, X² y X³ son cada uno en forma independiente CR⁵ o N; R⁵ es un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; R¹ es un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; R² es un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; Y¹, Y² e Y³ son cada uno en forma independiente CR⁶ o N; y R⁶ es un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013143940 | 2013-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096848A1 true AR096848A1 (es) | 2016-02-03 |
Family
ID=51220851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102528A AR096848A1 (es) | 2013-07-09 | 2014-07-08 | Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9199963B2 (es) |
| EP (1) | EP3019487A1 (es) |
| JP (1) | JP2016523809A (es) |
| CN (1) | CN105358544A (es) |
| AR (1) | AR096848A1 (es) |
| CA (1) | CA2917490A1 (es) |
| TW (1) | TW201536767A (es) |
| UY (1) | UY35650A (es) |
| WO (1) | WO2015005489A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2802571A1 (en) * | 2012-01-12 | 2014-11-19 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
| JPWO2013168759A1 (ja) * | 2012-05-10 | 2016-01-07 | 武田薬品工業株式会社 | 芳香環化合物 |
| AU2020406139A1 (en) | 2019-12-20 | 2022-06-30 | Bayer Aktiengesellschaft | Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof |
| HUP2200222A1 (hu) | 2022-06-17 | 2023-12-28 | Richter Gedeon Nyrt | MCHR1 antagonisták a Prader-Willi szindróma kezelésére |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849708A (en) | 1995-06-06 | 1998-12-15 | Joslin Diabetes Center, Inc. | Promotion of eating behavior |
| AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| EP0848060A3 (en) | 1996-12-11 | 2000-02-02 | Smithkline Beecham Corporation | Novel human 11CB splice variant |
| CA2682108C (en) | 1997-09-05 | 2013-12-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| JP2001525178A (ja) | 1997-12-03 | 2001-12-11 | スミスクライン ビーチャム コーポレーション | ヒト１１ｃｂスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法 |
| WO2000049170A1 (en) | 1999-02-18 | 2000-08-24 | Smithkline Beecham Corporation | MURINE 11cby RECEPTOR |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1285651B1 (en) | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonists |
| CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| US7544690B2 (en) | 2001-10-01 | 2009-06-09 | Taisho Pharmaceutical Co., Ltd. | MCH receptor antagonists |
| US7101845B2 (en) | 2002-01-31 | 2006-09-05 | Joslin Diabetes Center, Inc. | Methods of modulating β cell function |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| US20060183789A1 (en) | 2002-09-25 | 2006-08-17 | Lavanya Rajachandran | Methods for preventing and treating obesity in patients with mc4 receptor mutations |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| US7960369B2 (en) | 2002-11-08 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| WO2004048363A1 (ja) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | イミダゾール誘導体、その製造法および用途 |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| NL1026826C2 (nl) | 2003-08-13 | 2007-01-04 | Pharmacia Corp | Gesubstitueerde pyridinonen. |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005040824A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24) |
| JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
| WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| CA2560111A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US20100184648A1 (en) | 2005-03-29 | 2010-07-22 | Akira Gomori | Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease |
| WO2006112549A1 (ja) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | COMPOUND OF PHENOXYALKANOIC ACID |
| BRPI0615150A2 (pt) | 2005-08-10 | 2017-06-20 | Takeda Pharmaceuticals Co | agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
| JP4401428B2 (ja) | 2006-06-27 | 2010-01-20 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| MY158052A (en) | 2006-10-19 | 2016-08-30 | Takeda Pharmaceutical | Indole compound |
| US7825261B2 (en) | 2006-12-05 | 2010-11-02 | National Taiwan University | Indazole compounds |
| JP2010515745A (ja) | 2007-01-10 | 2010-05-13 | アルバニー モレキュラー リサーチ， インコーポレイテッド | ５−フロピリジノン置換インダゾール |
| KR20090101370A (ko) * | 2007-01-10 | 2009-09-25 | 알바니 몰레큘라 리써치, 인크. | 5-피리디논 치환된 인다졸 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| WO2008099794A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| US20120316200A1 (en) * | 2010-04-12 | 2012-12-13 | Merck Sharp & Dohme Corp. | Pyridone derivatives |
| WO2011127643A1 (en) | 2010-04-12 | 2011-10-20 | Merck Sharp & Dohme Corp. | Pyridone derivatives |
| EP2802571A1 (en) | 2012-01-12 | 2014-11-19 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
-
2014
- 2014-07-08 CN CN201480039259.5A patent/CN105358544A/zh active Pending
- 2014-07-08 AR ARP140102528A patent/AR096848A1/es unknown
- 2014-07-08 WO PCT/JP2014/068651 patent/WO2015005489A1/en not_active Ceased
- 2014-07-08 UY UY35650A patent/UY35650A/es not_active Application Discontinuation
- 2014-07-08 EP EP14742376.8A patent/EP3019487A1/en not_active Withdrawn
- 2014-07-08 US US14/325,564 patent/US9199963B2/en not_active Expired - Fee Related
- 2014-07-08 TW TW103123436A patent/TW201536767A/zh unknown
- 2014-07-08 JP JP2016500830A patent/JP2016523809A/ja active Pending
- 2014-07-08 CA CA2917490A patent/CA2917490A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150018373A1 (en) | 2015-01-15 |
| US9199963B2 (en) | 2015-12-01 |
| TW201536767A (zh) | 2015-10-01 |
| CN105358544A (zh) | 2016-02-24 |
| EP3019487A1 (en) | 2016-05-18 |
| CA2917490A1 (en) | 2015-01-15 |
| JP2016523809A (ja) | 2016-08-12 |
| UY35650A (es) | 2015-02-27 |
| WO2015005489A1 (en) | 2015-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118312A2 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
| SV2017005472A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| MX2016000143A (es) | Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. | |
| AR102977A1 (es) | Inhibidores de erk | |
| AR089527A1 (es) | Inhibidores de bromodominios | |
| EA201692219A1 (ru) | Способы получения противовирусных соединений | |
| AR106138A1 (es) | Compuestos y métodos para inhibir jak | |
| AR111983A1 (es) | ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR090836A1 (es) | Derivados de benzamida | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR097932A1 (es) | Antagonista del receptor de somatostatina del subtipo 5 (sstr5) | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR096848A1 (es) | Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) | |
| EA201591645A1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре | |
| AR093057A1 (es) | Inhibidores de la syk | |
| CU24248B1 (es) | Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato como antagonistas del receptor-h3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |